Overview
Wade Iams is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Iams is rated as an Experienced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer. Dr. Iams is currently accepting new patients.
His clinical research consists of co-authoring 80 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Non-Hodgkin Lymphoma.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
4220 Harding Pike, Nashville, TN 37205
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
5 Clinical Trials
Sarah Cannon Research Institute
Dr. Patel joined SCRI in 2024, as director of lymphoma research, and oversees SCRI’s comprehensive lymphoma clinical trial portfolio. Previously, he served as the Director of Hematologic Malignancies and Cell Therapy at the Swedish Cancer Institute in Seattle, Washington, where he led development of the program’s clinical standards for lymphoma care, assisted in the expansion of cell therapy services, and helped shape lymphoma research efforts. Dr. Patel was also a member of the Paul G. Allen Research Center at Seattle Cancer Institute, serving as a co-founding member of the Center for Immuno-oncology, where he collaborated on translational research related to immunotherapy in hematologic diseases.Dr. Patel has been published in various medical journals, including New England Journal of Medicine, Blood, and Journal of Clinical Oncology. He is also a member of the ASCO Cancer Communications Committee, the CIBMTR Lymphoma Working Committee, and the National Planning Committee for the Lymphoma Research Foundation Lymphoma Rounds. His clinical and research focus is in lymphomas, CLL, and cellular therapy. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Vanderbilt Health Clinicians, LLC
Nishitha Reddy is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Reddy is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL), Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration. Dr. Reddy is currently accepting new patients.
Vanderbilt Health Clinicians, LLC
David Morgan is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Morgan is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration. Dr. Morgan is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Lung CancerDr. Iams isElite. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
- Distinguished
- ALK-Positive Non-Small Cell Lung CancerDr. Iams isDistinguished. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- EGFR Positive Lung CancerDr. Iams isDistinguished. Learn about EGFR Positive Lung Cancer.
- Large-Cell Lung CarcinomaDr. Iams isDistinguished. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Iams isDistinguished. Learn about Lung Adenocarcinoma.
- Pleuropulmonary BlastomaDr. Iams isDistinguished. Learn about Pleuropulmonary Blastoma.
- Squamous Cell Lung CarcinomaDr. Iams isDistinguished. Learn about Squamous Cell Lung Carcinoma.
- Advanced
- MesotheliomaDr. Iams isAdvanced. Learn about Mesothelioma.
- Neuroendocrine TumorDr. Iams isAdvanced. Learn about Neuroendocrine Tumor.
- Posterior Fossa TumorDr. Iams isAdvanced. Learn about Posterior Fossa Tumor.
- Primitive Neuroectodermal Tumor (PNET)
- Experienced
- Anal CancerDr. Iams isExperienced. Learn about Anal Cancer.
- Familial Colorectal CancerDr. Iams isExperienced. Learn about Familial Colorectal Cancer.
- Hemolytic Transfusion ReactionDr. Iams isExperienced. Learn about Hemolytic Transfusion Reaction.
- HER-2 Positive Breast CancerDr. Iams isExperienced. Learn about HER-2 Positive Breast Cancer.
- Lung NodulesDr. Iams isExperienced. Learn about Lung Nodules.
- MelanomaDr. Iams isExperienced. Learn about Melanoma.